PsOPsA Hub’s Post

New publication 📝 Results from the phase II GAP trial published in the Journal of the American Academy of Dermatology International by Wilsmann-Theis et al. show that the primary endpoint was met with a 59.6% reduction in PPPASI at Week 24 with guselkumab in patients with moderate-to-severe palmoplantar pustulosis. Learn more: https://loom.ly/EJR3PXg #psoriasis #MedNews #MedEd

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics